Source: Annual Congress 2004 - Lung fibrosis sarcoidosis alveolar microlithiasis and proteinosis
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
S. Boniface, F. Milhe, J. Y. Gaubert, M. Badier, B. Chetaille, M. Reynaud-Gaubert, A. Magnan (Marseilles, France). Successful treatment by GMCSF of pulmonary alveolar proteinosis relapsing after a first GMCSF course. Eur Respir J 2004; 24: Suppl. 48, 4091

Member's Comments

No comment yet.

Related content which might interest you: Treatment of severe pulmonary alveolar proteinosis using inhaled GM-CSF Source: Annual Congress 2010 - Rare diffuse lung diseases Year: 2010 Rituximab therapy in autoimmune pulmonary alveolar proteinosis Source: Eur Respir J 2009; 33: 1503-1506 Year: 2009 Inhaled GM-CSF for autoimune pulmonary alveolar proteinosis Source: Short video statement 2020 Year: 2020 Treatment of pulmonary alveolar proteinosis (PAP) with administration of GM-CSF Source: Eur Respir J 2002; 20: Suppl. 38, 447s Year: 2002 Plasmapheresis for treatment of pulmonary alveolar proteinosis Source: Eur Respir J 2009; 33: 1220-1222 Year: 2009 Pulmonary alveolar proteinosis: failure of treatment by bronchoscopic lobar lavages and GM-CSF treatment in a child Source: Eur Respir J 2003; 22: Suppl. 45, 309s Year: 2003 Reduced GM-CSF autoantibody in improved lung of autoimmune pulmonary alveolar proteinosis Source: Eur Respir J 2012; 39: 777-780 Year: 2012 Pulmonary alveolar proteinosis Source: Respipedia Article Year: 2017 Neutralizing capacity of autoantibody against GM-CSF in patients with autoimmune pulmonary alveolar proteinosis Source: International Congress 2018 – Pitfalls in the diagnosis and management of rare diffuse parenchymal lung diseases (DPLDs) Year: 2018 Granulocyte-macrophage colony stimulating factor inhalation therapy as a treatment for pulmonary alveolar proteinosis Source: Eur Respir J 2003; 22: Suppl. 45, 377s Year: 2003 Inhaled GM-CSF in pulmonary alveolar proteinosis (PAP) patient refractory to plasmapheresis combined with multiple whole lung lavages (WLL) Source: International Congress 2016 – Orphan diseases I Year: 2016 Aerosol granulocyte-macrophage colony-stimulating factor for pulmonary alveolar proteinosis Source: Eur Respir J 2006; 27: 585-593 Year: 2006 An open-label trial of rituximab therapy in pulmonary alveolar proteinosis Source: Eur Respir J 2011; 38: 1361-1367 Year: 2011 The effect of pentoxifylline on IL-12 and IL-18 release by alveolar macrophages in sarcoidosis and hypersensitivity pneumonitis versus idiopathic pulmonary fibrosis Source: Eur Respir J 2003; 22: Suppl. 45, 377s Year: 2003 CTGF and TNFa expression in alveolar macrophages of patients with idiopathic pulmonary fibrosis before and after treatment with azathioprine and interferon-g Source: Annual Congress 2009 - Idiopathic pulmonary fibrosis: concepts and mechanisms Year: 2009 The analysis of alveolar macrophage form in secondary pulmonary alveolar proteinosis complicated with myelodysplastic syndrome. Source: International Congress 2017 – Rare diseases Year: 2017 Idiopathic pulmonary alveolar proteinosis: GM CSF therapy and whole lung lavage a case report Source: Eur Respir J 2003; 22: Suppl. 45, 44s Year: 2003 Autoimmune pulmonary alveolar proteinosis complicated with sarcoidosis: clinical courses and serum levels of anti-GM-CSF autoantibody Source: International Congress 2018 – Pitfalls in the diagnosis and management of rare diffuse parenchymal lung diseases (DPLDs) Year: 2018 Inhalation therapy of interferon-gamma in patients with idiopathic pulmonary fibrosis Source: Eur Respir J 2005; 26: Suppl. 49, 266s Year: 2005 Intercurrent intractable factors in autoimmune pulmonary alveolar proteinosis Source: Annual Congress 2009 - Various backgrounds in diffuse parenchymal lung disease Year: 2009